| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 3.4K | 3.5% | 11.8% |
| Total Income | 3.6K | 2.3% | 6.8% |
| Expenditure | 2.9K | 4.9% | 2.1% |
| PBT | 656.18 | 29.7% | 27.9% |
| Net Profit | 559.42 | 35.2% | 31.7% |
| OPM | 26.34% | 3.55pp | 4.15pp |
| NPM | 15.73% | 4.36pp | 2.98pp |
| EPS | 13.44 | 35.8% | 30.5% |
Mankind Pharma Approves Audited FY26 Financial Results
19 May 2026 · 19 May, 7:32 pm
Summary
Mankind Pharma Limited reported financial updates for Q4 & FY26.
Informational and educational content only. Not investment advice.